A Randomized Multicenter Study of Daylight Mediated Photodynamic Therapy (PDT)
Not Applicable
Completed
- Conditions
- Actinic Keratoses
- Registration Number
- NCT00711178
- Lead Sponsor
- Bispebjerg Hospital
- Brief Summary
A randomised, multi-center study of daylight mediated photodynamic therapy (PDT) with Metvix in patients with multiple actinic keratosis on the face and/or scalp.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- 18 years and older, 5 AK in face and scalp
Exclusion Criteria
- immunosuppression
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method response rate 3 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of methyl aminolevulinate in daylight mediated photodynamic therapy for actinic keratosis?
How does daylight mediated photodynamic therapy compare to traditional PDT in treating facial and scalp actinic keratosis?
Which biomarkers correlate with response to methyl aminolevulinate-based photodynamic therapy in actinic keratosis patients?
What adverse events are associated with Metvix daylight PDT and how are they managed in clinical practice?
Are there combination therapies involving methyl aminolevulinate and 5-aminolevulinic acid derivatives for actinic keratosis treatment?
Trial Locations
- Locations (1)
Bispebjerg Hospital
🇩🇰Copenhagen, Denmark
Bispebjerg Hospital🇩🇰Copenhagen, Denmark